All In MedTech

Device Trial Radar · NCT03784027

The Artificial Pancreas in Very Young Children With T1D

Open-label, Multi-centre, Multi-national, Randomized 2-period Crossover Study Comparing Closed-loop Insulin Delivery With Sensor-augmented Pump Therapy Over 4 Months in Children 1-7 Years With Type 1 Diabetes at Home, With an Extension.

Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

May 1, 2019

Primary completion

Feb 22, 2021

Study completion Oct 3, 2022

Sponsor

Lead sponsor
University of CambridgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission; Cambridge University Hospitals NHS Foundation Trust; The Leeds Teaching Hospitals NHS Trust; University of Luxembourg; University of Leipzig; Medical University of Graz; Medical University Innsbruck; Medical University of Vienna; Jaeb Center for Health Research; University of Edinburgh; Stanford University; Glooko
First posted
Dec 21, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 1 year, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF. It evaluates the use of the Artificial Pancreas (closed loop system) in very young children with type 1 diabetes (T1D) aged 1-7 years. This outcome study aims to determine whether 24/7 automated closed loop glucose control improves time in range compared to sensor augmented pump therapy. An extension phase will evaluate the effect of long-term home use of the 24/7 automated hybrid closed loop insulin delivery system on glucose control (UK sites only). The study employs an open-label, multi-centre, multi-national, randomized, two-period, crossover design. Participants undergo a 2-4 week run-in period, followed by two 16-week treatment periods (one for each therapy) separated by a 1-4 week washout. The order of treatments is randomized. Up to 80 young children (with a target of 72 randomized subjects) on insulin pump therapy will be recruited from paediatric outpatient diabetes clinics. Before using the study devices, participants and their parents/guardians receive training on the safe use of the study pump, continuous glucose monitoring (CGM) device, and hybrid closed loop system. Nursery or school carers may also be trained if needed. During the closed loop arm, subjects use the system for 16 weeks under free-living conditions at home and in nursery/school without remote monitoring. In the control arm, subjects use sensor augmented pump therapy for 16 weeks under similar conditions, with regular contact and 24/7 telephone support from the study team. The primary endpoint is the time spent in the target glucose range (3.9-10.0 mmol/l) as recorded by CGM. Secondary outcomes include the time spent with glucose levels above and below target and other CGM metrics. Safety assessments include the frequency and severity of hypoglycaemic episodes and diabetic ketoacidosis (DKA). In the extension phase, participants have follow-up contacts every 3 months, with the primary endpoint measured over 18 months from the end of the primary phase and compared to sensor augmented pump therapy during that phase. Secondary outcomes, safety, and utility will be assessed similarly.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • CamAPS FXDevice

    CamAPS FX closed loop system comprises: * Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) * Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) * An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor * Cloud upload system to monitor CGM/insulin data

  • Sensor augmented therapyOther

    Study insulin pump and study CGM.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time in Target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl)Time frame: 16-week home stay

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical University of Graz Department of Pediatrics and Adolescent Medicine

    Graz, Austria

  • Medical University of Innsbruck Department of Pediatrics I

    Innsbruck, Austria

  • Medical University of Vienna Department of Pediatrics

    Vienna, Austria

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.